Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...